France· FR:64776785
ERLOTINIB TEVA FRANCE 25 mg, comprimé pelliculé
A medicinal product containing chlorhydrate d'erlotinib, registered in France by TEVA (PAYS-BAS), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CHLORHYDRATE D'ERLOTINIB
- Manufacturer
- TEVA (PAYS-BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930138007plaquette(s) aluminium PVC de 30 comprimé(s)EUR 194.66
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Chlorhydrate d'erlotinib in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsErlotinib Amarox 25 mg filmomhulde tablettenAmarox Pharma B.V.
- United StatesErlotinibAurobindo Pharma Limited
- FinlandErlotinib AvansorAvansor Pharma Oy
- SwedenErlotinib Avansor 25 mg Filmdragerad tablettAvansor Pharma Oy
- SpainERLOTINIB CIPLA 25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGCipla Europe
- BelgiumErlotinib EG 25 mgEG
- PolandErlotinib KrkaKrka, d.d., Novo mesto
- IcelandErlotinib KrkaKrka, d.d., Novo mesto
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Belgium · Erlotinib Sandoz
- Bulgaria · Ерлотиниб Актавис, Ерлотиниб Крка
- Cyprus · Erlotinib Remedica
- Czechia · Erlotinib Krka, Erlotinib Teva
- Germany · Erlotev, Erlotinib Axiromed
- Denmark · Erlotinib "stada", Erlotinib Krka
- Estonia · Erlotinib Viatris
- Spain · Erlotinib Sandoz, Erlotinib Tarbis
- Finland · Erlotinib Krka, Erlotinib Stada
- United Kingdom (Northern Ireland) · Erlotinib Amarox, Erlotinib Glenmark
- Greece · Erlotinib Faran, Erlotinib Teva
- Croatia · Erlotinib Alpha-Medical, Erlotinib Krka
- Hungary · Erlotinib Actavis, Erlotinib Krka
- Iceland · Erlotinib Krka, Erlotinib Teva
- Italy · Erlotinib Mylan, Erlotinib Sandoz
- Liechtenstein · Tarceva
- Lithuania · Erlotinib Viatris, Varlota
- Latvia · Erlotinib Sandoz, Erlotinib Viatris
- Netherlands · Erlotinib Accordpharma, Erlotinib Amarox
- Norway · Erlotinib Krka, Tarceva
- Poland · Erlotinib Zentiva
- Portugal · Erlotinib Mylan, Erlotinib Qritou
- Romania · Erlotinib Krka, Erlotinib Viatris
- Sweden · Erlotinib Krka, Erlotinib Medical Valley
- Slovenia · Erlotinib Krka, Erlotinib Teva
- Slovakia · Erlotinib Sandoz, Erlotinib Stada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ae1846c5-f72a-4e46-ba72-5b6aa87a8a50 GET /v1/drugs/ae1846c5-f72a-4e46-ba72-5b6aa87a8a50?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64776785",
"date_amm": "2018-02-14",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"substance": "CHLORHYDRATE D'ERLOTINIB",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about chlorhydrate d'erlotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.